Gilead Sciences | GILD - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
AbbVie USD 6.57B 2.82B 2026-06
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
ALKERMES USD 511.53M 159.98M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Amgen USD 13.99B 1.95B 2026-06
Biogen USD 1.28B 2.1B 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Coherus Biosciences USD 82.92M 32.32M 2026-06
Eli Lilly USD 8.95B 3.67B 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Glaxosmithkline GBP 3.44B 146M 2026-03
Incyte USD 3.98B 33.45M 2026-06
J&J USD 20.42B 1.27B 2026-06
Merck USD 6.85B 1.52B 2026-06
Moderna USD 1.72B 185M 2026-06
Neurocrine Biosciences USD 332.4M 65.9M 2026-06
Novartis USD 7.62B 739M 2026-06
Pfizer USD 976M 727M 2026-06
PTC Therapeutics USD 1.05B 215.9M 2026-06
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 6.35B 806M 2026-06
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
United Therapeutics USD 1.8B 523.5M 2026-06
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06